Advertisement

Specialty News

June 19, 2017
June 19, 2017
The Oral Rheumatoid Arthritis trial (ORAL) Strategy assessed the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and...
The Oral Rheumatoid Arthritis trial (ORAL) Strategy assessed the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate.
MORE
June 19, 2017
June 19, 2017
Clovis Oncology Inc said its ovarian cancer drug rucaparib camsylate (Rubraca) slowed disease progression in a late-stage trial involving patients...
Clovis Oncology Inc said its ovarian cancer drug rucaparib camsylate (Rubraca) slowed disease progression in a late-stage trial involving patients with various gene mutations who had undergone initial therapy.
MORE
June 09, 2017
June 09, 2017
Some prominent cancer doctors plan to use clinical trials to show that many oncology medications could be taken at lower doses or for shorter...
Some prominent cancer doctors plan to use clinical trials to show that many oncology medications could be taken at lower doses or for shorter periods without hurting their effectiveness. A pilot study by the group of doctors involving a widely prescribed drug for advanced prostate cancer.
MORE
May 23, 2017
May 23, 2017
Pharmacists can fill a gap in care by expanding their injectable medication administration services beyond immunization, according to a report...
Report of Stakeholder Conference on Improving Patient Access to Injectable Medications available online in JAPhA
MORE
May 18, 2017
May 18, 2017
FDA expanded on Wednesday the approved use of ivacaftor (Kalydeco—Vertex Pharmaceuticals) for treating cystic fibrosis. The decision expands the...
FDA expanded on Wednesday the approved use of ivacaftor (Kalydeco—Vertex Pharmaceuticals) for treating cystic fibrosis. The decision expands the number of rare gene mutations that the drug can now treat from 10 mutations to 33.
MORE
May 09, 2017
May 09, 2017
PTC Therapeutics said Monday that it would receive a net price of $35,000 annually per patient for deflazacort (Emflaza), the muscular dystrophy...
PTC Therapeutics said Monday that it would receive a net price of $35,000 annually per patient for deflazacort (Emflaza), the muscular dystrophy drug it acquired from Marathon Pharmaceuticals in April.
MORE
May 08, 2017
May 08, 2017
FDA has approved edaravone (Radicava—Mitsubishi Tanabe Pharma America) for the treatment of patients with amyotrophic lateral sclerosis (ALS), also...
FDA has approved edaravone (Radicava—Mitsubishi Tanabe Pharma America) for the treatment of patients with amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig's disease.
MORE
May 04, 2017
May 04, 2017
The World Health Organization (WHO) announced plans to launch a pilot program for prequalifying biosimilar medications. Beginning this September,...
The World Health Organization (WHO) announced plans to launch a pilot program for prequalifying biosimilar medications.
MORE
May 04, 2017
May 04, 2017
Updated results for an ongoing study showcase the viability of treating hepatitis C virus (HCV) with imported, and thereby more affordable, generic...
Updated results for an ongoing study showcase the viability of treating hepatitis C virus (HCV) with imported, and thereby more affordable, generic versions of direct-acting antivirals.
MORE
April 28, 2017
April 28, 2017
FDA has expanded the approved use of regorafinib (Stivarga—Bayer HealthCare Pharmaceuticals) to include treatment of patients with hepatocellular...
FDA has expanded the approved use of regorafinib (Stivarga—Bayer HealthCare Pharmaceuticals) to include treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This is the first FDA-approved treatment for a liver cancer in nearly 10 years.
MORE

Pages